Skip to menu Skip to content Skip to footer
Professor Victoria Atkinson
Professor

Victoria Atkinson

Email: 

Overview

Background

Associate Professor Victoria Atkinson is both a Senior Medical Oncologist and a Principal Investigator for clinical trials in the adjuvant and metastatic setting at the Princess Alexandra Hospital and Greenslopes Private Hospital (in collaboration with Gallipoli Medical Research Foundation). Additionally, she is an Associate Professor with the University of Queensland, Clinical School of Medicine. Associate Professor Atkinson’s research interests are in the field of Oncology, and she has extensive experience in targeted-therapies and immunotherapies. Her main research interests are melanoma and gastro-intestinal oncology. Associate Professor Atkinson is passionate about trying to improve outcome for all patients with advanced melanoma as well as advanced gastro-intestinal cancers.

Associate Professor Atkinson has been involved in the clinical development of the current targeted and immunotherapies in melanoma over the past decade bringing these therapies into clinical practice. She has been involved in advocating for patient access to these therapies for patients in Queensland and Australia from guidelines through to reimbursement policies. These therapies have revolutionised the lives of patients and brought about the longest median overall survival for advanced melanoma. However there still remains significant work to be done in therapy resistant disease and she continues to work with therapies towards overcoming resistance.

In the past 5 years, Associate Professor Atkinson has been an Invited Speaker at 22 national and international meetings including Medical Oncology Group of Australia ASM Immunotherapy Symposium, New Zealand Society for Medical Oncology meeting and the Society for Melanoma Research congress. A/Prof Atkinson has published 82 publications, 31 oral abstracts and 65 posters. Associate Professor Atkinson is actively involved in the research supervision of her basic and advanced trainees, and resident medical officers who demonstrate interest in a project. She has supervised trainees to complete their research projects and supported 6 Australian research poster presentations, and 10 international research poster presentations.

She is passionate and motivated to continue to change practice by bringing clinically important and relevant trials to Queensland and to mentor trainees and junior consultants to continue this tradition.

Availability

Professor Victoria Atkinson is:
Available for supervision

Research interests

  • Oncology

  • Melanoma

  • Gastro-intestinal oncology

  • Patient outcomes

Works

Search Professor Victoria Atkinson’s works on UQ eSpace

124 works between 2011 and 2025

101 - 120 of 124 works

2017

Conference Publication

Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1)

da Silva, Ines Esteves Domingues Pires, Johnpulle, Romany Anne Nilanthi, Banks, Patricia Diana, Grass, G. Daniel, Smith, Jess Louise, Everett, Ashlyn S., Goldinger, Simone M., -Thomson, Rachel Roberts, Millward, Michael, Glitza, Isabella Claudia, Haydu, Lauren Elaine, Atkinson, Victoria, Wang, Tim, Eroglu, Zeynep, Conry, Robert Martin, Shackleton, Mark J., Hong, Angela, Long, Georgina V., Johnson, Douglas Buckner and Menzies, Alexander M. (2017). Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-07, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9513

Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1)

2017

Journal Article

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., Klein, O., Hassel, J. C., Sosman, J. A., Guminski, A., Sullivan, R. J., Ribas, A., Carlino, M. S., Davies, M. A., Sandhu, S. K. and Long, G. V. (2017). Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 28 (2), 368-376. doi: 10.1093/annonc/mdw443

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

2017

Conference Publication

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

Tobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

2017

Journal Article

The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma

Ladwa, Rahul and Atkinson, Victoria (2017). The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma. Melanoma Research, 27 (2), 168-170. doi: 10.1097/CMR.0000000000000336

The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma

2017

Conference Publication

Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent Immunotherapy

Caldwell, Reece, Mason, Robert and Atkinson, Victoria (2017). Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent Immunotherapy. COSA's 44th Annual Scientific Meeting, Immunotherapy: Molecules and Mountains, Sydney, NSW Australia, 13–15 November 2017. Hoboken, NJ United States: Wiley.

Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent Immunotherapy

2016

Journal Article

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists

Atkinson, Victoria, Long, Georgina V., Menzies, Alexander M., McArthur, Grant, Carlino, Matteo S., Millward, Michael, Roberts-Thomson, Rachel, Brady, Benjamin, Kefford, Richard, Haydon, Andrew and Cebon, Jonathan (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists. Asia Pacific Journal of Clinical Oncology, 12 (S7), 5-12. doi: 10.1111/ajco.12656

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: guidelines from Australian melanoma medical oncologists

2016

Conference Publication

Complete responders to anti-PD1 antibodies. What happens when we stop?

Atkinson, V. G. and Ladwa, R. (2016). Complete responders to anti-PD1 antibodies. What happens when we stop?. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.11

Complete responders to anti-PD1 antibodies. What happens when we stop?

2016

Conference Publication

Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access program

Ladwa, R., Andelkovic, V. and Atkinson, V. (2016). Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access program. Implementation + Innovation in Immunotherapy, Gold Coast, QLD, Australia, 3-5 August 2016. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12542

Pembrolizumab for metastatic melanoma: results of the complete responders on the named patient access program

2015

Journal Article

Sentinel node biopsy for melanoma: The medical oncology perspective

Menzies, Alexander M., Atkinson, Victoria G., Brown, Michael P., Carlino, Matteo S., Cebon, Jonathan, Guminski, Alexander, Kefford, Richard F., Long, Georgina V., McArthur, Grant, McNeil, Catriona M., Millward, Michael and Sandhu, Shahneen (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44 (12), 875-876.

Sentinel node biopsy for melanoma: The medical oncology perspective

2015

Conference Publication

Pembrolizumab for metastatic melanoma - one year results of named patient access program

Atkinson, Victoria G., Andelkovic, Vladimir and Gunawan, Benjamin (2015). Pembrolizumab for metastatic melanoma - one year results of named patient access program. COSA’s 42nd Annual Scientific Meeting. Rare Cancers: Common Goals, Hobart, TAS, Australia, 17-19 November 2015. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12432_2

Pembrolizumab for metastatic melanoma - one year results of named patient access program

2015

Journal Article

Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix

Sparks, David S., Morris, Bradley, Xu, Wen, Fulton, Jessica, Atkinson, Victoria, Meade, Brian and Lutton, Nicholas (2015). Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix. International Surgery, 100 (1), 21-28. doi: 10.9738/INTSURG-D-14-00089.1

Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix

2015

Journal Article

Nivolumab in Previously Untreated Melanoma without a BRAF mutation

Robert, Caroline, Long, Georgina, Brady, Benjamin, Dutriaux, Caroline, Miao, Michele, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinsk-Warzocha, Ewa, Savage, Kerry, Hernberg, Michaela, Lebbe, Cleste, Charles, Julie, Mihalcioiu, Caitlin, Chiarion-Sileni, Vanna, Mauch, Conrelia, Cognetti, Francesco, Arance, Ana, Schmidt, Kenrik, Schadendorf, Dirk, Gogas, Helen, Lundgren-Erikkson, Lotta, Horak, Christine, Sharkey, Brian, Waxman, Ian, Atkinson, Victoria and Ascierto, Paolo (2015). Nivolumab in Previously Untreated Melanoma without a BRAF mutation. The New England Journal of Medicine, 372 (4), 320-330. doi: 10.1056/NEJMoa1412082

Nivolumab in Previously Untreated Melanoma without a BRAF mutation

2015

Journal Article

Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.

Gorayski, Peter, Dzienis, Marcin, Foote, Matthew, Atkinson, Victoria, Burmeister, Elizabeth and Burmeister, Bryan (2015). Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.. Asia Pacific Journal of Oncology, 13 (2), E117-E123. doi: 10.1111/ajco.12345

Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.

2015

Conference Publication

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

Privthviraj, Prashanth, McArthur, Grant, Atkinson, Victoria, Parente, Phillip, Andrews, Miles Cameron, Parakh, Sagun, Cebon, Jonathon and Klein, Oliver (2015). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

2015

Conference Publication

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.

Larkin, James M. G., Yan, Yibing, McArthur, Grant A., Ascierto, Paolo Antonio, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev V., Stroyakovskiy, Daniil, Thomas, Luc, De La Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Wongchenko, Matthew, Rooney, Isabelle Anne, Chang, Ilsung, Hack, Stephen Paul, Dreno, Brigitte and Ribas, Antoni (2015). Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.. American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology.

Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:Phase III study of cobimetinib plus vemurafenib in advanced BRAF-mutated melanoma.

2015

Conference Publication

Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma(MEL): Results of a Phase III study (Checkmate066)

Long, Georgina V., Atkinson, Victoria, Ascierto, Paolo Antion, Robert, Caroline, Hassel, Jessica Cecile, Rutkowski, Piotr, Savage, Kerry, Taylor, Fiona, Coon, Cheryl, Gilloteau, Isabelle, Dasanti, Homa, Waxman, Ian and Pickar Abernethy, Amy (2015). Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma(MEL): Results of a Phase III study (Checkmate066). American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology.

Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma(MEL): Results of a Phase III study (Checkmate066)

2014

Journal Article

Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma

Larkin, James, Ascierto, Paolo, Dren, Brigette, Atkinson, Victoria, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Sovak, Mika, Chang, Ilsung, Choong, Nicholas, Hack, Stephen, McArthur, Grant A. and Ribas, Antoni (2014). Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma. The New England Journal of Medicine, 371 (20), 1867-1876. doi: 10.1056/NEJMoa1408868

Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma

2014

Journal Article

BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib

McClenahan, Phil, Lin, Lynlee L., Tan, Jean-Marie, Flewell-Smith, Ross, Schaider, Helmut, Jagirdar, Kasturee, Atkinson, Victoria, Lambie, Duncan, Prow, Tarl W., Sturm, Richard A. and Soyer, Peter (2014). BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib. JAMA Dermatology, 150 (10), 1079-1082. doi: 10.1001/jamadermatol.2014.436

BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib

2014

Conference Publication

Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study

Martin-Algarra, Salvador, Cebon, Jonathan, Neyns, Bart, Brown, Ewan, Puertolas, Teresa, Garcia, Yolanda, Atkinson, Victoria, Crown, John, Lau, Mike, Dalland, Lindi, Stein, Dara, Payne, Krista, Aktan, Gursel, Jobanputra, Minesh, Queirolo, Paola and Millward, Michael (2014). Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study. Society for Melanoma Research, Zurich, Switzerland, November 2014. Hoboken, NJ United States: Wiley-Blackwell Publishing. doi: 10.1111/pcmr.12317

Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study

2014

Journal Article

Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review

Dzienis, Marcin and Atkinson, Victoria (2014). Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review. Melanoma Research, 24 (4), 349-353. doi: 10.1097/CMR.0000000000000068

Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review

Funding

Current funding

  • 2023 - 2026
    Assessment of tumour phenotype for precision medicine in oesophageal cancer via deep learning analysis of medical images
    CCQ Accelerating Collaborative Cancer Research
    Open grant
  • 2018 - 2025
    A Randomised Phase III Study of the duration of the Anti-PD1 - therapy in metastatic melanoma (STOP-GAP)
    NHMRC Project Grant
    Open grant

Past funding

  • 2021 - 2025
    Novel predictive disease modelling using liquid biopsies to improve outcomes in melanoma (MRFF Genomics Health Futures Mission grant led by the University of Melbourne)
    University of Melbourne
    Open grant
  • 2020 - 2025
    Circulating tumour DNA guidEd Therapy for stage IIB/C BRAF mutant positive mElanoma after surgiCal resecTION (DETECTION) (MRFF ICTC led by University of Melbourne)
    University of Melbourne
    Open grant
  • 2020 - 2021
    Cancer Evolution Biobank
    PA Research Foundation
    Open grant

Supervision

Availability

Professor Victoria Atkinson is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Professor Victoria Atkinson's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au